Australia Mammography Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035)

Market Overview

The Australia mammography market is entering a technology transition. Most screening still relies on two-dimensional digital units, but governments have now committed to assess and then introduce tomosynthesis and artificial intelligence reading nationally, which will reshape what clinics buy over the next decade.

Three forces are shaping the market: a national framework that moves screening from age-based invitations towards risk tiers, density notification and annual screening for some women; replacement demand from public and private fleets; and radiologist workforce pressure that favours software able to support double reading.

In April 2025 the BreastScreen Australia Review recommended a plan for tomosynthesis as the primary modality, in July 2026 BreastScreen SA began a randomised artificial intelligence trial, and in August 2026 governments endorsed the Strategic Framework for the program.

Key Market Trends and Insights

• National reform framework: Governments endorsed the BreastScreen Australia Strategic Framework in August 2026, with modelling suggesting reform could cost up to AUD 2 billion over the decade.
• Participation gap: BreastScreen Queensland set a participation target of 60% by 2032 in January 2025, up from 51.3%, signalling sustained demand for screening capacity.
• AI reading trial: BreastScreen SA's randomised trial, launched in July 2026, compares two radiologists against one radiologist working with software over six to nine months.
• Private sector scale: Sonic Healthcare reported Australian radiology revenue of AUD 1,037 million for the year to June 2026, up 6.9%, reflecting the buying power of private imaging groups.

Australia Mammography Market Size and Forecast

The market is moving from two-dimensional digital fleets sold on price towards tomosynthesis, contrast-enhanced imaging and software-assisted reading sold on workflow and detection value. Mammography systems still lead because every clinic must buy or replace hardware, while software and artificial intelligence and tomosynthesis advance fastest as governments plan national implementation. New South Wales remains the largest base, and Queensland grows quickest from a smaller one. A national framework, density notification and risk-based screening underpin a durable multi-year outlook in which procurement follows policy decisions and radiologist capacity rather than a short equipment cycle.

Key Takeaways: Australia Mammography Market

Policy Now Sets Purchasing Direction

Revenue is set to rise from AUD 140.00 million in 2025 to AUD 270.30 million in 2035 at a 6.8% CAGR, as the national framework turns technology choices into funded programs.

Software and Tomosynthesis Lead Growth

Mammography systems remain the largest component, but software and artificial intelligence grow at an estimated 12.1% CAGR and tomosynthesis at 9.2% through 2035, as trials in New South Wales and South Australia move towards routine use.

Reform Milestones Shape Demand

The August 2026 framework sets staged actions that influence timing of equipment replacement and software licensing across public and private services.

• Feasibility assessment of tomosynthesis before national rollout
• Density notification and pilots for women aged 45 to 49
• Cost-sharing principles to be agreed between governments

Australia Mammography Market Report Summary

Key Insight

Policy reform, fleet replacement and reading software shape demand. Software and tomosynthesis advance fastest while conventional digital systems remain the installed base across screening services and private clinics.

Key Trends in the Australia Mammography Market

The Australia mammography market is being reshaped by risk-based screening reform, early artificial intelligence adoption in state programs, density reporting and a national push towards tomosynthesis.

October 2026 - BreastScreen NSW Advances AI-Supported Reading

• BreastScreen NSW was a finalist in the 2026 NSW Health Awards for using artificial intelligence to support radiologists reading mammograms.
• The program describes itself as the first population-based screening program in Australia to introduce this technology and now gives each person a breast density result.
• It reports fewer false-positive recalls, shorter follow-up waits and a validation process showing radiologist workload can fall without lowering quality.

August 2026 - Governments Endorse BreastScreen Australia Strategic Framework

• The framework, covered by AusDoc on 18 August 2026, introduces density notification, pilots for women aged 45 to 49 and a national annual screening policy.
• It plans two risk tiers, assessment of tomosynthesis feasibility and, in the medium term, national implementation of artificial intelligence and tomosynthesis.
• The Limbic reported on 13 August 2026 that modelling put reform costs at up to AUD 2 billion, with AUD 1.3 million announced to start.

July 2026 - BreastScreen SA Launches Randomised AI Trial

• BreastScreen SA launched its trial on 6 July 2026, assigning volunteers to two independent radiologists or one radiologist working with Australian-developed software.
• The trial runs for six to nine months, is funded through the Medical Research Future Fund, and keeps a radiologist as the final decision maker.
• Partners include BreastScreen Victoria, the University of Melbourne, Monash University and Adelaide University.

April 2025 - Review Recommends Tomosynthesis Plan and AI Governance

• The BreastScreen Australia Review final report summary, dated 29 April 2025, recommended an evidence-based plan for tomosynthesis as the primary screening modality.
• It noted that adoption is challenged by longer reading times, training needs and resourcing, and called for an artificial intelligence governance framework.
• It also found about half of eligible women are screened, well below the 70% biennial target.

Key Insight

Policy is moving from review to staged delivery, with density reporting and artificial intelligence reading already live in one state and tomosynthesis assessment now a stated national priority.

Recent Market Developments in the Australia Mammography Market

Recent developments, presented from the most recent, show the Australia mammography market moving from ownership change and provider results into new product launches that supply the next equipment cycle.

October 2026 - Jardine Matheson Completes I-MED Acquisition

• Jardine Matheson completed its acquisition of I-MED Radiology Network on 1 October 2026.
• I-MED operates 215 diagnostic imaging clinics across Australia and New Zealand, making it one of the largest private buyers of mammography equipment.
• The new owner gives the network a long-term capital base for equipment renewal and digital tools.

August 2026 - Sonic Healthcare and Integral Diagnostics Report Results

• Sonic Healthcare reported on 20 August 2026 that Australian radiology revenue reached AUD 1,037 million, up 6.9%, with EBITDA of AUD 248.7 million.
• Integral Diagnostics reported on 25 August 2026 revenue of AUD 788.7 million across 142 sites, with 468 reporting radiologists.
• Both groups pointed to new greenfield sites and expanded MRI, which compete with mammography for capital but add women's imaging capacity.

April 2026 - Blackstone and TPG Complete Hologic Take-Private

• Funds managed by Blackstone and TPG completed their acquisition of Hologic on 7 April 2026, delisting it from Nasdaq.
• Shareholders received US$76 per share in cash plus a contingent value right of up to US$3.
• The contingent payments depend on Breast Health revenue goals, tying the owners to mammography growth.

November 2025 - GE HealthCare Unveils Pristina Recon DL

• GE HealthCare announced FDA authorisation of Pristina Recon DL on 25 November 2025, a deep learning reconstruction for three-dimensional mammography.
• It is an upgrade for the Pristina Via platform and uses two artificial intelligence models in sequence to reduce noise and artefacts.
• The company reported radiologists preferred its image quality in 99.1% of reviews against earlier reconstruction.

Key Insight

Ownership changes, provider results and new reconstruction software show capital and technology flowing into breast imaging, giving buyers more advanced options as national tomosynthesis planning begins.

Australia Mammography Industry Segmentation

The Expert Market Research’s report on the Australia Mammography Market offers a detailed analysis of the market based on the following segments.

Market Breakup by Technology

• Full-Field Digital Mammography
• Digital Breast Tomosynthesis
• Contrast-Enhanced Mammography
• Others

Full-Field Digital Mammography leads because the BreastScreen fleet and most private rooms still use two-dimensional units, and the April 2025 review described tomosynthesis adoption as constrained by reading time and training. Digital Breast Tomosynthesis grows fastest at an estimated 9.2% CAGR, as the August 2026 framework schedules feasibility assessment and later national implementation. Contrast-Enhanced Mammography is smaller but rising, with Siemens Healthineers announcing ClearCEM reconstruction in November 2025 and the Victorian MyScreen contrast imaging pilot announced in August 2026. Others cover breast ultrasound-linked and stereotactic biopsy systems.

Market Breakup by Component

• Mammography Systems
• Service and Maintenance
• Software and AI
• Accessories and Consumables
• Others

Mammography Systems lead because every clinic must buy or replace hardware, and ownership changes such as Jardine Matheson's October 2026 completion of I-MED support renewal budgets. Software and AI grows fastest at an estimated 12.1% CAGR after BreastScreen SA's July 2026 randomised trial and BreastScreen NSW's AI-supported reading. Service and Maintenance grows steadily as installed three-dimensional units need contracts, while Accessories and Consumables follow screening volumes, which the Queensland target of 60% participation by 2032 should lift.

Market Breakup by End User

• BreastScreen Services
• Private Radiology Clinics
• Hospitals and Public Breast Clinics
• Others

Private Radiology Clinics lead through large groups such as Sonic Healthcare, which reported Australian radiology revenue of AUD 1,037 million in August 2026, and Integral Diagnostics with 142 sites. BreastScreen Services grow fastest at an estimated 7.9% CAGR, as the framework schedules artificial intelligence and tomosynthesis for national use and the Townsville mobile van adds capacity. Hospitals and Public Breast Clinics expand with diagnostic and symptomatic demand, while Others cover mobile providers, research centres and academic trials.

Market Breakup by Region

• New South Wales
• Victoria
• Queensland
• Western Australia
• South Australia
• Others

New South Wales dominates through its large population, BreastScreen NSW's AI-supported reading and density results reported in October 2026, and I-MED and Sonic Healthcare networks, and grows at an estimated 6.5% CAGR. Queensland is fastest at an estimated 7.5%, helped by a participation target of 60% by 2032 and a new Townsville van announced in January 2025. Victoria grows at 6.7% with its MyScreen contrast pilot, Western Australia at 7.0%, and South Australia at 6.4% after its July 2026 AI trial. Others, grouping Tasmania, the Australian Capital Territory and the Northern Territory, grows at 6.3%.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Competitive Landscape in the Australia Mammography Market

Competition combines global equipment makers, large private radiology groups that buy in volume and software specialists. Entry barriers include therapeutic goods registration, local service engineering, integration with screening information systems and the tender relationships that anchor multi-year supply to state programs.

Hologic

Hologic, headquartered in Marlborough, Massachusetts, develops breast imaging systems including three-dimensional mammography and the Genius AI Detection software, and supplies Australian screening and private practices. On 7 April 2026 funds managed by Blackstone and TPG completed its take-private, with Joe Almeida becoming chief executive. Contingent value rights of up to US$3 per share depend on Breast Health revenue goals, so mammography is central to its owners' return.

GE HealthCare

GE HealthCare, headquartered in Chicago, Illinois, supplies the Pristina mammography range to Australian hospitals and imaging groups. On 25 November 2025 it announced FDA authorisation of Pristina Recon DL, a deep learning reconstruction upgrade for the Pristina Via platform. The company reported radiologists preferred its image quality in 99.1% of reviews against prior reconstruction, and said the platform offers zero-click acquisition and 99% uptime.

Siemens Healthineers

Siemens Healthineers, headquartered in Erlangen, Germany, sells the Mammomat B.brilliant tomosynthesis platform through its Australian subsidiary. At RSNA on 30 November 2025 it announced ClearCEM reconstruction for contrast-enhanced mammography, plus contrast-guided biopsy support with targeting accuracy of plus or minus 1 millimetre. The company says the upgrades reduce the need to switch modalities, though ClearCEM was pending United States clearance at announcement.

I-MED Radiology Network

I-MED Radiology Network is an Australian imaging group, headquartered in Sydney, operating 215 clinics across Australia and New Zealand. On 20 February 2026 it announced the acquisition of Radiology Group, adding clinics in Greater Western Sydney and the Hunter, with PET and MRI expansion planned. Jardine Matheson completed its acquisition of I-MED on 1 October 2026, giving the network a new owner for equipment renewal.

Other players operating in the Australia mammography market include Fujifilm, Sonic Healthcare, Integral Diagnostics, Lumus Imaging, and Volpara Health, alongside regional distributors, service engineering firms and artificial intelligence developers supporting BreastScreen services and private clinics across Australia.

Key Insight

Competition rests on image quality, software capability, service reach and tender relationships rather than price alone. Global makers supply hardware while large radiology groups concentrate buying power.